Investment Rating - The report maintains an investment rating of "Outperform" with a target price set for leading stocks [3][4]. Core Insights - The innovative drug sector is experiencing fluctuations, but several catalysts are anticipated, including academic conferences, business development achievements, and negotiations for medical insurance [2]. - The National Medical Insurance Administration has updated the data on innovative drugs included in the medical insurance directory, showing rapid hospital admissions for several newly included domestic innovative drugs [2][22]. Summary by Sections Weekly New Drug Market Review - From August 4 to August 10, 2025, the top five companies in the new drug sector by stock price increase were: Beihai Kangcheng (+73.1%), Jiahe Biotech (+39.0%), Gilead Sciences (+30.3%), Heyu Biotech (+21.1%), and Hengrui Medicine (+15.3%). The top five companies with the largest declines were: Hutchison China MediTech (-13.8%), Frontier Biotech (-13.4%), Yifang Biotech (-11.7%), Haichuang Pharma (-9.9%), and Maiwei Biotech (-9.2%) [1][16]. Recommended Stocks to Watch - The report suggests focusing on potential overseas licensing opportunities for significant products, including differentiated GLP-1 assets from companies like Zhongsheng Pharma, Kangyuan Pharma, and Gilead Sciences. Additionally, upgraded PD-1 products from Kangfang Biotech and others are highlighted [2][22]. Key Analysis of the New Drug Industry - The report notes that several innovative drugs newly included in the medical insurance directory are rapidly entering hospitals, with notable growth in hospital admissions for drugs such as Zaiqiang Pharma's recombinant thrombin and Hengrui Medicine's Tazemetostat [2][22][23]. New Drug Approval and Acceptance Status - This week, three new drug applications were approved, including Adalimumab injection from Wuhan Biological Products Research Institute, Dulaglutide injection from Shandong Boan Biotech, and Evinacumab injection from Xi'an Janssen [28][29]. Additionally, four new drug applications were accepted, including Trastuzumab injection from Amgen and others [28][30]. Clinical Application Approval and Acceptance Status - A total of 55 new drug clinical applications were approved this week, while 31 new drug clinical applications were accepted [10][31].

Investment Rating - The report maintains an investment rating of "Leading the Market - A" [9] Core Insights - The report highlights that several newly included innovative drugs in the medical insurance directory are rapidly entering hospitals, with significant growth in the number of drugs entering hospitals by the end of May 2025 compared to April 2025 [2][22] - The report notes that the new drug sector has shown a strong performance, with notable increases in stock prices for companies such as Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), and Junsheng Tai (29.4%) during the week of July 7 to July 13, 2025 [1][18] Summary by Sections Weekly New Drug Market Review - From July 7 to July 13, 2025, the top five companies in the new drug sector by stock price increase were Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), Junsheng Tai (29.4%), Kaituo Pharmaceutical (20.7%), and Yongtai Biotech (20.1%) [1][18] - The top five companies by stock price decrease were Yiming Anke (-19.4%), Shenzhou Cell (-13.4%), Ascentage Pharma (-10.0%), Lepu Biotech (-8.9%), and Rongchang Biotech (-8.8%) [1][18] Key Analysis of the New Drug Industry - The National Medical Insurance Administration updated the hospital admission data for innovative drugs included in the medical insurance directory as of the end of May 2025, indicating rapid hospital admissions for several newly included domestic innovative drugs [2][22] - Notable drugs with fast admission growth included Kangfang Biotech's Cardunilumab and Ivorisumab, Shanghai Yizhong's Paclitaxel Micelle, and Zecjin Pharmaceutical's Recombinant Human Thrombin [2][22] New Drug Approval and Acceptance Status - Four new drug or new indication applications were approved this week, including Ascentage Pharma's Lisatoclax tablets and Zhejiang Tianyuan's quadrivalent influenza virus split vaccine [26][27] - Ten new drug applications were accepted, including Dali Yingjie’s Docetaxel Injection and Zhaoke Pharmaceutical's Atropine Sulfate Eye Drops [26][28] Clinical Application Approval and Acceptance Status - This week, 43 new drug clinical applications were approved, and 20 new drug clinical applications were accepted [4][28]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to see significant revenue growth, with total revenue projected to reach CNY 11.49 billion in 2025, representing a year-on-year increase of 21.96% [1] - The company has entered a commercialization phase for its chronic disease pipeline, which is anticipated to create a second growth curve alongside its oncology products [8] - The company aims to achieve a domestic sales target of CNY 20 billion by 2027 and plans to have five pipelines enter global Phase III studies by 2030 [8] - The IBI363 product, targeting immune-oncology, is highlighted for its potential breakthroughs in various patient populations and has received two FDA Fast Track Designations [8] - The report emphasizes the company's ongoing internationalization efforts and the expected acceleration of its product portfolio [8] Financial Projections - Revenue forecasts for 2025 and 2026 are CNY 11.49 billion and CNY 15.18 billion, respectively, with net profit projections of CNY 574.47 million and CNY 2.19 billion [1] - The company is expected to achieve profitability as its product mix expands and costs are effectively managed, with a projected net profit of CNY 3.03 billion by 2027 [8] - The current market capitalization corresponds to a P/E ratio of 157 for 2025, 41 for 2026, and 30 for 2027 [8]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to see significant revenue growth, with total revenue projected to reach RMB 11.49 billion in 2025, representing a year-on-year increase of 21.96% [1] - The company has entered a commercialization phase for its chronic disease pipeline, which is anticipated to create a second growth curve alongside its oncology products [8] - The company aims to achieve a domestic sales target of RMB 20 billion by 2027 and plans to have five pipelines enter global Phase III studies by 2030 [8] - The IBI363 product, targeting immune-oncology, is highlighted for its potential breakthroughs in various patient populations and has received two FDA Fast Track Designations [8] - The report forecasts a net profit of RMB 574.47 million in 2025, with a substantial increase to RMB 3.03 billion by 2027, indicating a strong recovery and profitability trajectory [1] Financial Projections - Total revenue is projected to grow from RMB 9.42 billion in 2024 to RMB 20.09 billion by 2027, with a compound annual growth rate (CAGR) of approximately 32.36% [1] - The net profit is expected to turn positive in 2025, reaching RMB 574.47 million, and further increasing to RMB 3.03 billion by 2027 [1] - The earnings per share (EPS) is projected to improve from RMB -0.06 in 2024 to RMB 1.84 in 2027, reflecting a strong recovery in profitability [1]